FDFatima Dakroub

Fatima Dakroub

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fatima Dakroub has a total of 104 co-authors. Here are the top co-authors by number of shared publications:

  • Ghassan Dbaibo

    Department of Pediatrics and Adolescent Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon

    4 shared publications
  • Celina F. Boutros

    Center for Infectious Diseases Research (CIDR) and WHO Collaborating Center for Reference and Research on Bacterial Pathogens, Faculty of Medicine, American University of Beirut, Beirut, Lebanon

    3 shared publications
  • Firas Kobeissy

    Center for Neurotrauma, Multiomics & Biomarkers, Department of Neurobiology and Neuroscience Institute, Morehouse School of Medicine (MSM), Atlanta, Georgia

    3 shared publications
  • Ghassan M. Matar

    Department of Experimental Pathology, Immunology, and Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon

    3 shared publications
  • Abdullah Shaito

    Biomedical Research Center (BRC), QU Health, Qatar University, Doha P.O. Box 2713, Qatar

    2 shared publications
  • Ali Hussein Eid

    Department of Basic Medical Sciences, College of Medicine, QU Health Qatar University Doha Qatar

    2 shared publications

Latest Publications

  • Open Access

    Outbreak of Mycoplasma pneumoniae infection in Lebanon during 2023–2024

    by Dima Khreis, Mona Bou Khdoud, Elsy El Tawil, Zeinab El Zein, Celina F. Boutros, Fatima Dakroub, Nagham Hamzah, Ali Ismail, Salman Mroueh, Rima Hanna-Wakim, et al.

  • Open Access

    Tracking the shifting landscape of SARS-CoV-2 variants in Lebanon among healthcare workers and hospitalized patients

    by Habib Alkalamouni, Mirna Bou Hamdan, Farouk Abou Hassan, Fatima Dakroub, Lama Hamadeh, Alissar Rady, Moubadda Assi, Nada Ghosn, Rami Mahfouz, Carine Sakr, et al.

    Genomic surveillance of SARS-CoV-2 is critical for tracking viral evolution and informing public health responses. This study characterized variants circulating among healthcare workers (HCWs) and hospitalized patients in Lebanon between January 2022 and September 2024. A total of 530 SARS-CoV-2-positive nasopharyngeal swabs were collected from five Lebanese governorates and subjected to whole-genome sequencing. Correlations between variant circulation and a number of demographic and clinical variables were assessed. Most HCWs were female (64%), young adults (20–30 years, 39%), and had no comorbidities (97%). In contrast, hospitalized patients were mostly older adults (>60 years, 55.6%) with underlying conditions (77%). Early 2022 was marked by BA.1- and BA.2-like Omicron variants, followed by the predominance of BA.5-like lineages. In 2023, recombinant XBB sublineages became widespread. By 2024, these were largely replaced by next-generation variants, including JN.1 and KP.3.1.1. Despite differences in demographics and exposure risk, both groups showed parallel variant evolution. These findings reflect global and regional patterns and highlight the dynamic nature of SARS-CoV-2 circulation in Lebanon. IMPORTANCE: This study provides a comprehensive snapshot of SARS-CoV-2 variant evolution in Lebanon between 2022 and 2024, focusing on healthcare workers and hospitalized patients. By combining genomic and clinical data, it reveals how successive Omicron subvariants emerged and spread within key population groups. The detection of diverse and evolving lineages, including XBB recombinants and next-generation variants such as JN.1, underscores the ongoing antigenic drift of SARS-CoV-2. These insights reinforce the value of continued genomic surveillance for pandemic preparedness, especially in regions where data remain limited. Understanding local variant dynamics can guide targeted vaccination strategies and health policy decisions.


  • The impact of pre-graft serology on the risk of BKPyV infection reactivation post-renal transplantation

    by Fatima El Zahraa Dakroub

    L'impact de la sérologie pré-greffe sur le risque re réactivation du BKPyV après une transplantation rénale: Contexte: La néphropathie associée au virus polyomavirus BK (BKPyVAN) est une maladie incommodante observée chez les receveurs de greffe rénale immunodéprimés suite à une réactivation du polyomavirus BK (BKPyVV). BKPyVAN peut évoluer vers un dysfonctionnement de la greffe et n'a actuellement aucun traitement, rendant la réduction de l'immunosuppression comme seul choix de gestion. Cependant, cette réduction s'avère inadaptée ou non applicable conduisant à une augmentation du risque de rejet aigu. Ainsi, des marqueurs prédictifs de réactivation de l'infection à BKPyV sont nécessaires pour l'identification des patients à haut risque. Méthodes: nous avons mené une étude rétrospective pour évaluer la corrélation entre le statut sérologique du BKPyV en pré-transplantation et l'incidence de l'infection par BKPyV en post-transplantation. Des sérums de 329 receveurs et 222 donneurs appariés ont été testés pour les anticorps anti-BKV contre quatre sérotypes de BKV par un test IgG ELISA à base de VLPs, et la charge d'ADN du BKPyV a été surveillée pendant au moins 1 an après la transplantation par PCR. Résultats: 80 (24%) receveurs étaient viruriques et 59 (18%) receveurs étaient virémiques en post-transplantation. Un risque élevé de virémie à BKPyV a été observé pour les receveurs qui avaient un titre moyen d'anticorps pour tous les sérotypes ≤ 400 avant la transplantation (Odds ratio [OR], 5.58; intervalle de confiance à 95% [IC], 2.60-11.79; P 4 mois). Conclusions: Le titre moyen d'anticorps anti-BKPyV du donneur et du receveur peut servir d'outil prédictif pour gérer l'infection clinique avec BKPyV, en identifiant les patients à haut risque de réactivation du virus

  • Open Access

    Genomic characterization of invasive disease-causing Streptococcus pneumoniae in Lebanon, 2003–2025

    by Fatima Dakroub, Alannah C. King, Fata Akl, Alissar Zaghlout, Nancy Hourani, Harry Hung, Sarah Barada, Celina F. Boutros, Ana D. S. Ferreira, Lesley McGee, et al.

    Background . Streptococcus pneumoniae is a major human pathogen responsible for invasive pneumococcal diseases (IPDs). We utilized whole-genome sequencing to assess the impact of pneumococcal conjugate vaccines (PCVs) on the pneumococcal population causing IPD in Lebanon. Methods. S. pneumoniae isolates collected between 2003 and 2025 ( n =273) were sequenced and included in the study, which was divided into three periods. Private-PCV7 (2003–2009) and Private-PCV13 (2010–2015) correspond to the periods when the PCV7 and PCV13 vaccines were available only in the private healthcare sector, respectively. EPI-PCV13 (2016–2025) represents the period following PCV13 incorporation into the Expanded Program on Immunization (EPI). The Global Pneumococcal Sequencing (GPS) genome analysis pipeline was used to infer serotypes, genetic lineages, pilus locus and antimicrobial resistance (AMR) for 19 antibiotics. Phylogeny was constructed based on SNPs across the pneumococcal genome. Results. A total of 58 GPS clusters (GPSCs) expressing 40 serotypes were identified. Overall, serotypes 3, 14 and 19F were the most prevalent serotypes, while GPSC6, GPSC12 and GPSC1 were the most predominant pneumococcal lineages. We detected a significant increase in non-vaccine types (NVTs) after PCV7 and PCV13 introduction. In contrast, PCV7 serotypes declined significantly over the three study periods. Collectively, PCV7 serotypes were associated with significantly higher mortality (31.1%) compared to NVT (15.9%). Moreover, IPD-associated mortality was significantly higher among older adult patients (33.3%) compared to children aged ≤5 years (12.1%). Non-susceptibility to penicillin was the most prevalent resistance (62.1%), and multidrug resistance (MDR; non-susceptibility to at least three antibiotics) was identified in 36.4% of the isolates. MDR was primarily driven by GPSC1, GPSC9, GPSC6 and GPSC10. A significant decline in MDR and AMR against seven antibiotics was observed in the EPI-PCV13 period compared to previous study periods. Conclusions. Genomic surveillance is robust for tracking current NVT and identifying lineages that may influence future IPD trends in Lebanon. Given the high mortality rate detected in older adult IPD patients, implementing a routine immunization programme in this population may be beneficial.

  • Open Access

    Genomic and clinical epidemiology of SARS-CoV-2 in Lebanon: a prospective multicenter study 2020–2024

    by Fatima Dakroub, Celina F. Boutros, Diego Teixeira, Habib Alkalamouni, Nagham Hamzah, Nancy Hourani, Amani Haddara, Samar Dalle, Dima Khreis, Elsy Tawil, et al.

    Background: Globally, the trajectory of COVID-19 has been shaped by viral evolution, widespread vaccination and immunity from prior infections. We assessed the epidemiological and clinical patterns of COVID-19 in Lebanon between 2020 and 2024, identified the predominant SARS-CoV-2 clades and evaluated risk factors for COVID-19 associated mortality. Methods: This multicenter prospective study enrolled 1302 patients hospitalized with COVID-19 in Lebanon between November 2020 and October 2024. Multivariate logistic regression was used to determine predictors of COVID-19 associated mortality. Whole genome sequencing (WGS) was utilized to investigate the genomic epidemiology of SARS-CoV-2 and infer viral interactions between Lebanon and other countries. Multiple sequence alignment and phylogenetic analysis were conducted using the augur pipeline. Results: A progressive and significant reduction in severe outcomes, including pneumonia and mortality was observed throughout the study period. Pneumonia (AOR, 6.714; CI, 4.140–10.888; p < 0.0001) and age ≥ 60 years (AOR, 6.051; CI, 2.190–16.723; p = 0.001) were identified as independent predictors of COVID-19 mortality. Moreover, receiving 3 doses of a COVID-19 vaccine significantly reduced the odds of mortality (AOR, 0.229; CI, 0.108–0.486; p < 0.0001). Genomic analysis revealed multiple introductions of the same SARS-CoV-2 clades into Lebanon, which seeded local transmission chains. Conclusions: The transition of COVID-19 from pandemic to endemic in Lebanon was associated with reduced disease severity. Vaccination remains essential, particularly in older adult patients who are at high risk of mortality. Moreover, early diagnosis and management of pneumonia are crucial, given its association with COVID-19 mortality. Furthermore, WGS has proven valuable in tracking the local evolution of SARS-CoV-2 and its impact on clinical outcomes.

  • Open Access

    Comparison of Illumina and Oxford Nanopore Technology systems for the genomic characterization of Streptococcus pneumoniae

    by Fatima Dakroub, Fata Akl, Alissar Zaghlout, Jose Rita Gerges, Nancy Hourani, Celina F. Boutros, George F. Araj, Ghassan M. Matar, Antoine Abou Fayad, Ghassan S. Dbaibo, et al.

    Whole-genome sequencing (WGS) is an invaluable tool that enables high-resolution genotyping to precisely identify bacterial strains. It is particularly significant for highly pathogenic bacteria such as Streptococcus pneumoniae , a worldwide leading cause of mortality and morbidity. Illumina sequencing is highly established for S. pneumoniae , while Oxford Nanopore Technologies (ONT) data are limited. Hence, evaluating ONT-only data is needed. We aimed to compare the Illumina and ONT systems for S. pneumoniae sequencing. Moreover, we aimed to explore whether the newer chemistry from ONT with R10.4.1 flow cells improves the data outputs from long-read sequencing. S. pneumoniae bacteria were isolated from hospitalized patients with invasive pneumococcal disease (IPD) and serotyped by multiplex PCR. Resistance profiles were determined with anti-microbial susceptibility testing. A total of 27 isolates were sequenced using ONT Mk1c with R9.4.1 flow cells and Kit10 chemistry (ONT_V10) and the Illumina Miseq system. Illumina and ONT data were compared, and hybrid assembly was assessed. ONT sequencing was additionally performed with R10.4.1 flow cells and Kit14 chemistry (ONT_V14) in 12 isolates. S. pneumoniae identification, serotyping, AMR, and GPSC prediction were successfully achieved using ONT sequencing. The ONT_V14 chemistry significantly improved both MLST and pbp prediction in long-read sequencing. Overall, the hybrid assembly produced circular and contiguous genomes with high N50 parameters. Moreover, long-read assembly followed by short-read polishing is a fast and reliable approach for hybrid assembly at ONT sequencing depth >100×. For ONT sequencing depth Streptococcus pneumoniae . It represents an in-depth investigation of Illumina and Oxford Nanopore technologies (ONT) systems for bacterial sequencing. It sheds light on the performance of each platform in various aspects of sequencing, including raw and assembly statistics, capsular typing, pbp typing, GPSC, AMR, and MLST prediction. This study offers a comprehensive overview of S. pneumoniae genomics and a guide for clinical and research laboratories seeking to adopt bacterial sequencing by providing important considerations when choosing sequencing platforms and analysis pipelines. We report a strong case for the implementation of WGS in the clinical setting, based on its high concordance with conventional molecular and phenotypic methods. Furthermore, the flexibility and portability of the investigated pipelines facilitate their use in clinical applications.


  • Open Access

    Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis

    by Reem Halabi, Fatima Dakroub, Mohammad Z. Haider, Stuti Patel, Nayef A. Amhaz, Mohammad A. Reslan, Ali H. Eid, Yehia Mechref, Nadine Darwiche, Firas Kobeissy, et al.

    Meningiomas are the most prevalent primary intracranial tumors. The majority are benign but can undergo dedifferentiation into advanced grades classified by World Health Organization (WHO) into Grades 1 to 3. Meningiomas’ tremendous variability in tumor behavior and slow growth rates complicate their diagnosis and treatment. A deeper comprehension of the molecular pathways and cellular microenvironment factors implicated in meningioma survival and pathology is needed. This review summarizes the known genetic and epigenetic aberrations involved in meningiomas, with a focus on neurofibromatosis type 2 (NF2) and non-NF2 mutations. Novel potential biomarkers for meningioma diagnosis and prognosis are also discussed, including epigenetic-, RNA-, metabolomics-, and protein-based markers. Finally, the landscape of available meningioma-specific animal models is overviewed. Use of these animal models can enable planning of adjuvant treatment, potentially assisting in pre-operative and post-operative decision making. Discovery of novel biomarkers will allow, in combination with WHO grading, more precise meningioma grading, including meningioma identification, subtype determination, and prediction of metastasis, recurrence, and response to therapy. Moreover, these biomarkers may be exploited in the development of personalized targeted therapies that can distinguish between the 15 diverse meningioma subtypes.


  • Open Access

    Unveiling a Biomarker Signature of Meningioma: the Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis

    by Reem Halabi, Fatima Dakroub, Mohammad Z. Haider, Stuti Patel, Nayef A. Amhaz, Mohammad A. Reslan, Ali H. Eid, Yehia Mechref, Nadine Darwiche, Firas H. Kobeissy, et al.

    Meningiomas are the most prevalent primary intracranial tumors. The majority are benign but can undergo dedifferentiation into advanced grades classified by World Health Organization (WHO) into Grades 1 to 3. Meningiomas tremendous variability in tumor behavior and slow growth rates complicate their diagnosis and treatment. A deeper comprehension of the molecular pathways and cellular microenvironment factors implicated in meningioma survival and pathology is needed. This review summarizes the known genetic and epigenetic aberrations involved in meningioma, with a focus on Neurofibromatosis type 2 (NF2) and non-NF2 mutations. Novel potential biomarkers for meningioma diagnosis and prognosis are also discussed, including epigenetic-, RNA-, metabolomics, and protein-based markers. Finally, the landscape of available meningioma-specific animal models is overviewed. Use of these animal models can enable planning of adjuvant treatment, potentially assisting in preoperative and postoperative decision-making. Discovery of novel biomarkers will allow, in combination with WHO grading, more precise meningioma grading, including meningioma identification, subtype determination, and prediction of metastasis, recurrence, and response to therapy. Moreover, these biomarkers may be exploited in the development of personalized targeted therapies that can distinguish between the 15 diverse meningioma subtypes.

  • Pulmonary arterial hypertension and COVID-19: Piecing the puzzle

    by Fida Charif, Fatima Dakroub, Imad Bou Akl, Mithum Kularatne, David Montani